Abstract:Background Gait deviations, lower limb pain and joint stiffness represent key symptoms in patients with X-linked hypophosphatemia (XLH, OMIM 307800), a rare disorder of mineral homeostasis. While the pathomechanism for rickets is well understood, the direct role of PHEX (Phosphate-regulating neutral endopeptidase) deficiency in non-rachitic features including complex deformities, skull and dental affections remains unclear. FGF23-inhibiting antibody treatment can normalize serum phosphate levels and to improve rickets in XLH patients. However, linear growth remains impaired and effects on lower limb deformity and gait are insufficiently studied. Aims To characterize and evaluate the course of lower limb deformity in a case series of pediatric XLH patients receiving Burosumab therapy. Methods Comparative assessment of planar radiographs, gait analysis, biochemical and clinical features of pediatric patients before and ≥12 months after initiation of FGF23-inhibiting was performed prospectively. Lower limb maltorsion was quantified by torsional MRI and gait analysis. Standardized deformity analysis of lower limb anteroposterior radiographs was conducted. Results Seven patients (age 9.0 +/-3.6 years) were eligible for this study. All patients received conventional treatment before onset of antibody treatment. Maltorsion of the femur was observed in 8/14 legs using torsional MRI (mean antetorsion 8.79°). Maltorsion of the tibia was observed in 9/14 legs (mean external torsion 2.8°). Gait analysis confirmed MRI findings with femoral external malrotation prior to and one year after onset of Burosumab therapy. Internal foot progression (intoeing gait) remained pathological in all cases (mean 2.2°). Knee rotation was pathologically internal 10/14 legs. Mean mechanical axis deviation (MAD) of 16.1mm prior to Burosumab changed in average by 3.9mm. Three children underwent guided growth procedures within the observation period. Mild postprocedural rebound of frontal axis deviation was observed under Burosumab treatment in one patient. Conclusions This is the first study to investigate lower limb deformity parameters quantitatively in children with XLH receiving Burosumab. One year of Burosumab therapy was associated with persistent maltorsion and frontal axis deviation (varus/valgus) despite improved rickets in this small, prospective uncontrolled study.

High bone mineral apparent density in children with X-linked hypophosphatemia

Lumbar Spine Bone Mineral Apparent Density in Children: Results from the Bone Mineral Density in Childhood Study

Bone mineral density in adults with arthrogryposis multiplex congenita: a retrospective cohort analysis

Persistent Lower Limb Deformities Despite Amelioration of Rickets in X-Linked Hypophosphatemia (XLH) - A Prospective Observational Study

Insufficient Bone Mineralization to Sustain Mechanical Load of Weight in Obese Boys: A Cross-Sectional Study

Pediatric Bone Mineral Accrual Z‐Score Calculation Equations and Their Application in Childhood Disease

Bone Accrual Trajectories in Children and Adolescents with Perinatal HIV Infection

Age and Gender Differences in Vertebral Bone Marrow Adipose Tissue and Bone Mineral Density, Based on MRI and Quantitative CT

Lower limb maltorsion and acetabular deformity in children and adolescents with X-linked hypophosphatemia

Bone health of children with intestinal failure measured by dual energy X-ray absorptiometry and digital X-ray radiogrammetry

Unaffected bone mineral density in Danish children and adolescents with type 1 diabetes

Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study

Nephrocalcinosis and Kidney Function in Children and Adults with X-linked Hypophosphatemia: Baseline Results from a Large Longitudinal Study

Bone mineral density and other risk factors in children and adolescents with low-energy fractures of long bones

The natural course of bone mineral density in transgender youth before medical treatment; a cross sectional study

THU420 Analysis Of Factors Affecting Bone Mineral Density In Children And Adolescents With Systemic Lupus Erythematosus

Using bone mineral apparent density for BMD adjustment in chronic diseases: Thalassemia an example

X-Linked Hypophosphatemia, Not Only a Skeletal Disease But Also a Chronic Inflammatory State

Causality between Sex Hormones and Bone Mineral Density in Childhood: Age- and Tanner-Stage-Matched Sex Hormone Level May Be an Early Indicator of Pediatric Bone Fragility

Description of bone health in adolescents and young persons with Klinefelter syndrome - results from a pilot study

Bone mineral content and density of the lumbar spine of infants and toddlers: Influence of age, sex, race, growth, and human milk feeding